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CH-4058 Basel, SwitzerlandBackground & Aims: The liver performs a panoply of complex Lay summary: Liver diseases leading to organ failure may go
activities coordinating metabolic, immunologic and detoxifica- unnoticed as they do not trigger any symptoms or significant dis-
tion processes. Despite the liver’s robustness and unique self-
regeneration capacity, viral infection, autoimmune disorders,
fatty liver disease, alcohol abuse and drug-induced hepatotoxic-
ity contribute to the increasing prevalence of liver failure. Liver
injuries impair the clearance of bile acids from the hepatic portal
vein which leads to their spill over into the peripheral circulation
where they activate the G-protein-coupled bile acid receptor
TGR5 to initiate a variety of hepatoprotective processes.
Methods: By functionally linking activation of ectopically
expressed TGR5 to an artificial promoter controlling transcription
of the hepatocyte growth factor (HGF), we created a closed-loop
synthetic signalling network that coordinated liver injury-
associated serum bile acid levels to expression of HGF in a self-
sufficient, reversible and dose-dependent manner.
Results: After implantation of genetically engineered human
cells inside auto-vascularizing, immunoprotective and clinically
validated alginate-poly-(L-lysine)-alginate beads into mice, the
liver-protection device detected pathologic serum bile acid levels
and produced therapeutic HGF levels that protected the animals
from acute drug-induced liver failure.
Conclusions: Genetically engineered cells containing theranostic
gene circuits that dynamically interface with host metabolism
may provide novel opportunities for preventive, acute and
chronic healthcare.Journal of Hepatology 20
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excessive bile acid levels associated with liver injuries and auto-
matically produces a therapeutic protein in response. When inte-
grated into mammalian cells and implanted into mice, the circuit
detects the onset of liver injuries and coordinates the production
of a protein pharmaceutical which prevents liver damage.
 2016 European Association for the Study of the Liver. Published
by Elsevier B.V. Open access under CC BY-NC-ND license.Introduction
The liver is associated with over 500 functions which include the
clearance of the blood from toxic compounds, drugs and infec-
tious agents, the control of blood fat and glucose levels, and the
recovery, processing and conversion of digested food into meta-
bolic energy [1]. The processing of digested food requires the pro-
duction of bile and its major component, the bile acids. Bile acids
are synthesized from cholesterol in the liver, secreted by the hep-
atocytes into bile canaliculi and stored in the gall bladder [2].
After each meal, bile acids are released into the duodenum to
emulsify ingested fats and other lipophilic nutrients, reabsorbed
in the terminal ileum and transported back to the liver via the
portal vein, a process known as enterohepatic circulation [2,3].
Efficient clearance and recycling of bile acids from the portal vein
ensures low bile acid levels in the peripheral circulation, which
increase only marginally after each meal [2]. However, in patients
suffering from diverse liver diseases such as cirrhosis, cholestasis,
hepatitis and liver cancer, fasting blood bile acid levels are mark-
edly increased due to the impaired hepatic clearance of bile acids
from the portal vein [4–10]. Serum bile acid (SBA) levels therefore
serve as sensitive indicator of liver disease [4–10]. Because of the
minor daily meal-based fluctuations and their excessive levels
during liver-associated pathologies, SBAs have been suggested
to play a more prominent metabolic role exceeding the one of
emulsifying nutrients [2,11].
Indeed, bile acids have recently emerged as versatile sig-
nalling compounds endowed with systemic endocrine function16 vol. 65 j 84–94
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[2]. Bile acids are ligands of several nuclear hormone receptors
such as farnesoid X receptor (FXR) and G-protein-coupled recep-
tors (GPCR) such as TGR5 through which they activate diverse
signalling pathways that regulate triglyceride, cholesterol, glu-
cose and energy homeostasis as well as their own synthesis,
enterohepatic circulation, inflammation and liver regeneration
[2,11]. In particular, bile acid-mediated activation of TGR5 coor-
dinates renal clearance of bile acids, thereby preventing toxic bile
acid overload [11,12]. In addition, pro-inflammatory mediators
induce the production of hepatocyte growth factor (HGF), which
has a potent cytoprotective impact on hepatocytes, triggers their
proliferation and stimulates migration and proliferation of acti-
vated hepatic stem cells into the liver parenchyma, where the
cells differentiate into mature hepatocytes [13–15].
Liver diseases are particularly difficult to diagnose as latent
inflammations leading to critical fibrosis, irreversible cirrhosis
and organ failure may go unnoticed as they fail to trigger any
symptoms or significant discomfort [16,17]. To date, liver trans-
plantation is the major treatment option for late-stage liver
diseases [1]. However, because of the shortage of donor livers,
as well as the significant risk associated with transplantation and
life-long immunosuppression, a genetically engineered cell-based
theranostic liver-protection device combining precise diagnosis of
acute liver injuries with targeted therapeutic or hepatoprotective
interventions may represent an attractive alternative.
Capitalizing on SBAs as a well-established biomarker for a
wide variety of liver-associated pathologies [4–10], TGR5 as a
liver injury-specific bile acid sensor and HGF as a promising pro-
tein therapeutic validated in human clinical trials [18–21], we
have functionally linked these components using a synthetic
biology-based design strategy to create a closed-loop synthetic
gene network that detects the onset of liver injury, initiates
HGF-mediated liver regeneration and prevents liver failure.Materials and methods
Components of the liver-protection device
Comprehensive design and construction details for all expression vectors are pro-
vided in Table 1. The key components of the liver-protection device includes pBP2
for constitutive low-level expression of the human bile acid receptor TGR5
(PhCMV⁄-1-TGR5-pA) and pPB5, which produces human hepatocyte growth factor
in a bile acid-responsive TGR5-dependent manner (PCREm-HGF-pA).Cell culture and transfection
Human embryonic kidney cells (HEK-293, ATCC: CRL-11268 [HEK-293T]), baby
hamster kidney cells (BHK-21, ATCC: CCL-10), human fibrosarcoma cells (HT-
1080, ATCC: CCL-121) and telomerase-immortalised human mesenchymal stem
cells (hMSC-TERT, [22]) were cultured in Dulbecco’s modified Eagle’s medium
(DMEM; Invitrogen, Basel, Switzerland; cat. no. 52100-39) supplemented with
10% (v/v) fetal bovine serum (FBS; Sigma-Aldrich, Munich, Germany; cat. no.
F7524, lot no. 022M3395) or 10% (v/v) charcoal-stripped FBS (cFBS, Sigma-
Aldrich; cat. no. F6765, lot no. 13C443) and 1% (v/v) penicillin/streptomycin
solution (Sigma-Aldrich; cat. no. P4333). Wild-type Chinese hamster ovary cells
(CHO-K1, ATCC: CCL-61) were cultured in ChoMaster HTS (Cell Culture Tech-
nologies, Gravesano, Switzerland; cat. no. HTS-8) supplemented with 5% (v/v)
FBS and 1% penicillin/streptomycin solution. FreestyleTM 293-F suspension cells
(Life Technologies, Carlsbad, CA; cat. no. R79007) were cultivated in FreeStyleTM
293 Expression Medium (Life Technologies; cat. no. 12338018) supplemented
with 1% penicillin/streptomycin solution and grown in 12 well plates or shake
flasks placed on an orbital shaker (IKA KS 260 basic; IKA-Werke GmbH, Staufen
im Breisgau, Germany; cat. no. 0002980200) set to 100–150 rpm. All cell types
were cultivated at 37 C in a humidified atmosphere containing 5% CO2. All cellJournal of Hepatology 20lines were transfected using an optimized polyethyleneimine (PEI)-based
protocol [23]. For transfection of CHO-K1, HEK-293, BHK-21, HT-1080 and
hMSC-TERT, 5  104 cells seeded per well of a 24 well plate 20 h before transfec-
tion were incubated with a transfection solution containing 0.55 lg plasmid DNA
(for co-transfections equal amounts of plasmid DNA was used) and 2.2 ll of PEI
(polyethyleneimine; MW40,000, stock solution 1 lg/ll in ddH2O; Polysciences,
Eppelheim, Germany; cat. no. 24765-2). For transfection of suspension FreeStyleTM
293-F cells, 1  106 cells seeded per well of a 12 well plate 1 h before transfection
were incubated with a transfection solution containing 1.1 lg plasmid DNA and
4.4 ll PEI (1 lg/ll). The DNA/PEI transfection solution was mixed with 50 ll
150 mM NaCl, incubated for 15 min at 22 C and added dropwise to the cells. Cell
concentrations were profiled with a CASY Cell Counter and Analyser System
Model TT (Roche Diagnostics GmbH, Mannheim, Germany).
Animal experiments
Intraperitoneal genetically engineered cell implants were produced by
encapsulating pHY74/pSP16 (PhCMV⁄-1-eYFP-pA/PCREm-SEAP-pA)-, pPB2/pSP16
(PhCMV⁄-1-TGR5-pA/PCREm-SEAP-pA)-, pPB2/pPB5 (PhCMV⁄-1-TGR5-pA/PCREm-HGF-pA)-
and pPB7 (PhCMV-HGF-pA)-transgenic HEK-293 cells into coherent alginate-
poly-(L-lysine)-alginate beads (400 lm; 200 cells/capsule) using an Inotech
Encapsulator Research Unit IE-50R (Buechi Labortechnik AG, Flawil, Switzerland)
set to the following parameters: 25 ml syringe operated at a flow rate of 450
units, 200 lm nozzle with a vibration frequency of 1,020 Hz and 1.1 kV for bead
dispersion, stirrer speed at 4.5 units. 8 week-old female OF1 mice (oncins France
souche 1, Charles River Laboratory, Lyon, France) were intraperitoneally injected
with 2–5  106 cells (700 ll DMEM containing 1–2.5  104 capsules, 200 cells/
capsule) and were treated with bile acids (cholic acid [0–160 mg/kg] or taurour-
sodeoxycholic acid [0–160 mg/kg], twice-daily intraperitoneal injections of
0–80 mg/kg; cholic acid [0–160 mg/kg] or deoxycholic acid [0–80 mg/kg],
twice-daily intravenous injections of 0–80 mg/kg; cholic acid [0–160 mg/kg],
tauroursodeoxycholic acid [0–40mg/kg] or deoxycholic acid [0–160 mg/kg], twice
or fourth-daily oral administration of 0–40 mg/kg), hepatotoxicants (1-Naphtyl
isothiocyanate [75 mg/kg] or carbon tetrachloride [1 ml/kg], single oral dose) or
olive oil (8 ml/kg, single oral dose). Blood samples were collected 48 h after treat-
ment and the serum was isolated using BD Microtainer SST tubes according to
the manufacturer’s instructions (centrifugation for 5 min at 10,000 g; Becton
Dickinson, Plymouth, UK; cat. no. 365967). All mice were kept on a standard diet
(5 kcal % fat; Janvier S.A.S., Le Genest-Saint-Isle, France) unless indicated other-
wise. After completion of the experiments, the animals were sacrificed and their
liver collected for histological analysis. All experiments involving animals were
performed according to the directives of the European Community Council
(2010/63/EU), approved by the French Republic (no. 69266309 and no.
69266310; project no. DR2013-01 (v2)) and carried out by Ghislaine Charpin-El
Hamri and Marie Daoud-El Baba at the University of Lyon, Institut Universitaire
de Technologie (IUTA), F69622 Villeurbanne Cedex, France.
Histology
Two days after implantation of microencapsulated pPB2/pPB5-, pPB2/pSP16- or
pPB7-transgenic cells and subsequent oral administration of a single dose of ANIT
or olive oil, the mice were sacrificed and their livers were explanted. Five repre-
sentative liver slices (2–3 mm thick) of each animal were fixed in 0.1 M sodium
cacodylate buffer (pH7.4, 540 mOsm; Sigma-Aldrich, St. Louis, USA, cat. no.
CO250) containing 2.5% (v/v) glutaraldehyde (AGAR Scientific Ltd., Stansted, UK,
cat. no. R1010) and stored at 4 C until further processing. Tissue blocks of
approximately 1 mm3 were cut, rinsed in 0.1 M sodium cacodylate buffer
(3  10 min, pH 7.4, 340 mOsm) and post-fixed in 0.1 M sodium cacodylate buffer
containing 1% (w/v) osmium tetroxide (Electron Microscopy Sciences, Hatfield PA,
USA cat. no. 19100) at 4 C for 2 h. The samples were then washed in 0.1 M
sodium cacodylate buffer (3  10 min, pH 7.4, 340 mOsm), dehydrated by serial
incubation in ddH2O containing increasing concentrations of ethanol (70%, 80%,
90%, 96%, 99%, 100%) and embedded in EPON 812 (Fluka, Sigma-Aldrich, Buchs,
CH, cat. nos. 45245-45347). One lm thick liver sections were prepared using
glass knives, stained with toluidine blue (Fluka, Buchs, CH, cat. no. 89640) and
analysed by light microscopy (100–630 magnification, Imager M2, Zeiss, Jena,
De). At least five animals per treatment group were analysed.
Statistics
Results are expressed as mean ± SEM. Statistical significance of datasets was
evaluated by a two-tailed, unpaired Student’s t test using Graphpad Prism
V6.0d. p <0.05 was considered significant.16 vol. 65 j 84–94 85
Table 1. Plasmids used and designed in this study.
Plasmid Description and cloning strategy Reference or source
pBABE-puro Retroviral expression vector. [58]
pcDNA3.1(+) Mammalian expression vector (PhCMV-MCS-pA). Life Technologies, Carlsbad, CA
pEYFP-C1 Constitutive EYFP expression vector (PhCMV-EYFP-pA). Clontech, Mountain View, CA
pSEAP2-Control Constitutive SEAP expression vector (PSV40-SEAP-pA). Clontech, Mountain View, CA
pCMV-SPORT6 Mammalian expression vector (PhCMV-MCS-pA). Life Technologies, Carlsbad, CA
pBABE-puro HGF pBABE-puro containing full-length HGF cDNA. [59]
pTGR5 pCMV-SPORT6 containing a constitutive TGR5 expression unit (PhCMV-TGR5-pA). GenBank: BC033625
pCK53 PCRE-driven SEAP expression vector (PCRE-SEAP-pA). [60]
pMF111 PhCMV*-1-driven SEAP expression vector (PhCMV*-1-SEAP-pA). [61]
MKp37 Constitutive TetR-ELK1 expression vector (PhCMV-TetR-ELK1-pA). [62]
pSP16 PCREm-driven SEAP expression vector (PCREm-SEAP-pA). [63]
pHY57 PNFAT-driven shGLP1 expression vector (PNFAT-shGLP1-pA). [31]
pHY67 PCRE-driven shGLP1 expression vector (PCRE-shGLP1-pA). Ye et al., unpublished
pHY74 PhCMV*-1-driven EYFP expression vector (PhCMV*-1-EYFP-pA). EYFP 
was PCR-amplified from pEYFP-C1 using oligonucleotides OHY163 
(5’-gcgccgacgaattcGCCACCATGGTGAGCAAGGGCGAGGAGCTGTTCACC-3’) and OHY164 
(5’-cacgcacgaagcttTTACTTGTACAGCTCGTCCATGCC-3’), restricted with EcoRI/HindIII and 
cloned into the corresponding sites (EcoRI/HindIII) of pMF111.
This work 
pPB2 PhCMV*-1-driven TGR5 expression vector (PhCMV*-1-TGR5-pA). TGR5 was excised from pCMV-
SPORT6-TGR5 using EcoRI/HindIII and cloned into the corresponding sites (EcoRI/HindIII) 
of  pMF111.
This work
pPB5 PCREm-driven HGF expression vector (PCREm-HGF-pA). PCREm was PCR-amplified from 
pSP16 using oligonucleotides OPB29 (5’-TCTTACGCGTGCTAGCAGC-3’) and OPB39 
(5’-gcgaattcgcgaTTTACCAACAGTACCGGATT-3’), restricted with NheI/NruI and cloned into 
the corresponding sites (NheI/NruI) of pPB6.
This work
pPB6 PCRE-driven HGF expression vector (PCRE-HGF-pA). HGF was PCR-amplified from pBABE-
puro HGF using oligonucleotides OPB33 (5’-gcttcgaatcgcgaATTCGCCCACCATGTGGGTGA
CCAAA-3’) and OPB32 (5’-cgactctagaTTCAGCTATGACTGTGGTAC-3’), restricted with NruI/
XbaI and cloned into the corresponding sites (NruI/XbaI) of pCK53.
This work
pPB7
pPB8
Constitutive HGF expression vector (PhCMV-HGF-pA). HGF was PCR-amplified from pBABE-
puro HGF using oligonucleotides OPB50 (5’-cgcggatccACCATGTGGGTGACCAAA-3’) and 
OPB32 (5’-cgactctagaTTCAGCTATGACTGTGGTAC-3’), restricted with BamHI/XbaI and 
cloned into the corresponding sites (BamHI/XbaI) of pcDNA3.1(+).  
PCREm-driven shGLP1 expression vector (PCREm-shGLP1-pA). PCREm was excised from pSP16 
using KpnI/EcoRI and cloned into the corresponding sites (KpnI/EcoRI) of pHY57.
This work
This work
CRE, cAMP-response element; CREm, modified cAMP-response element; ELK1, ETS domain-containing transcription factor; ETS, E26 transformation-specific or E-twenty-six
transcription factor family; EYFP, enhanced yellow fluorescent protein; HGF, human hepatocyte growth factor; MCS, multiple cloning site; NFAT, nuclear factor of activated
T cells; pA, polyadenylation signal; PCRE, CRE containing synthetic mammalian promoter; PCREm, modified PCRE variant; PCR, polymerase chain reaction; PhCMV, human
cytomegalovirus immediate early promoter; PhCMVmin, minimal version of PhCMV; PhCMV⁄-1, tetracycline-responsive promoter (tetO7-PhCMVmin); PNFAT, synthetic mammalian
promoter containing a NFAT-response element; PSV40, simian virus 40 promoter; TetR, Escherichia coli Tn10-derived tetracyclinedependent repressor of the tetracycline
resistence gene; tetO7, TetR-specific heptameric operator sequence; TetR-ELK1, TetR-ELK1 fusion protein; SEAP, human placental secreted alkaline phosphatase; shGLP1,
short human glucagon-like peptide 1; TGR5, human bile acid receptor (GenBank: BC033625) also known as GPBAR1 (G protein–coupled bile acid receptor 1) or M-BAR
(membrane-type receptor for bile acids).
Oligonucleotides: Restriction endonuclease-specific sites are in italics and annealing base pairs are indicated in capital letters.
Research ArticleResults
Design and characterization of the synthetic mammalian bile acid
sensor
Bile acid-inducible activation of the human GPCR TGR5
triggers an intracellular signal transduction cascade involving
Gas-protein-mediated activation of the plasma membrane-bound
adenylate cyclase, which converts ATP into the second messenger
cyclic AMP (cAMP) [2]. Upon rewiring of the intracellular cAMP
surge via cAMP-dependent phosphokinase A (PKA)-mediated
activation of the cAMP-response element binding protein
(CREB1) to CREB1-specific synthetic promoters (PCRE, PCREm) con-
taining cAMP-response elements (CRE), bile acid levels could be
directly coupled to expression of a specific target gene (Fig. 1A).86 Journal of Hepatology 20Initial experiments using different expression platforms (pTGR5,
PhCMV-TGR5-pA; pPB2, PhCMV⁄-1-TGR5-pA) showed that TGR5
was efficiently transcribed (Supplementary Fig. 1A), produced
(Supplementary Fig. 1B) and triggered a bile acid (cholic acid)-
dependent cAMP surge (Supplementary Fig. 1C) in mammalian
cells. Since pPB2 provided optimal cholic acid-triggered trans-
gene expression when co-transfected with the reporter construct
pCK53 (PCRE-SEAP-pASV40; SEAP, human placental secreted alka-
line phosphatase) we used it as the preferred TGR5 expression
vector in all follow-up experiments (Fig. 1B). In order to further
improve tightness of the bile acid sensor we created PCREm
(pSP16; PCREm-SEAP-pA), a modified PCRE, that showed similar
bile acid-responsive induction kinetics and a comparable
dynamic range but exhibited lower leakiness and lower maxi-
mum expression levels compared to PCRE (Fig. 1C–1D). The bile16 vol. 65 j 84–94
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Fig. 1. Design and characterization of the synthetic mammalian bile acid sensor. (A) Design of a synthetic bile acid-triggered signalling cascade. The G protein-coupled
bile acid receptor 1 (TGR5) senses extracellular bile acids and triggers Gas-mediated activation of adenylate cyclase, which converts ATP to cyclic AMP (cAMP). cAMP binds
the regulatory subunits of protein kinase A (PKA), whose catalytic subunits translocate into the nucleus where they phosphorylate the cAMP-responsive binding protein 1
(CREB1). Subsequently, CREB1 binds and activates target gene transcription from synthetic promoters PCRE engineered to contain different CREB1 response elements (CRE).
(B) Cholic acid-inducible transgene expression in HEK-293 cells using different TGR5 expression vectors. HEK-293 cells were co-transfected with pCK53 (PCRE-SEAP-pA;
100 ng) and either pTGR5 (PhCMV-TGR5-pA; 1000 ng) or pPB2 (PhCMV⁄-1-TGR5-pA; 1000 ng) and cultivated in the presence or absence CA (100 lM). HEK-293 cells
transfected with pSEAP2-Control (PSV40-SEAP-pA; 100 ng) were used as control. SEAP levels in the culture supernatants were scored after 24 h. Data presented are
mean ± SD, n P3. (C) SEAP expression kinetics. HEK-293 cells were co-transfected with pPB2 (PhCMV⁄-1-TGR5-pA; 1000 ng) and either pCK53 (PCRE-SEAP-pA; 100 ng) or
pSP16 (PCREm-SEAP-pA; 100 ng) and cultivated for 72 h in the presence or absence of CA (100 lM). SEAP levels in the culture supernatants were scored every 24 h. Data
presented are mean ± SD, n P3. (D) Dose-dependent SEAP expression. HEK-293 cells were co-transfected with pPB2 (PhCMV⁄-1-TGR5-pA; 1000 ng) and either pSP16
(PCREm-SEAP-pA; 100 ng) or pCK53 (PCRE-SEAP-pA; 100 ng) and cultivated for 24 h in the presence of different CA concentrations (0–200 lM) before SEAP levels in the
culture supernatants were scored. Data presented are mean ± SD, n P3. (E) Bile acid-inducible SEAP expression in different mammalian cell lines. hMSC, Freestyle 293F,
HEK-293, BHK-21, HT-1080 and CHO-K1 cells were co-transfected with pPB2/pSP16 (1000 ng/100 ng) and cultivated in medium containing different bile acid derivatives
(CA: 100 lM; tauroursodeoxycholic acid TUDCA: 100 lM; deoxycholic acid DCA: 100 lM for hMSC, BHK-21, HT-1080, CHO-K1 and HEK-293, 10 lM for Freestyle 293F).
SEAP levels in the culture supernatant were scored 24 h after addition of bile acids. Data presented are mean ± SD, n P3. (F) Reversibilty of cholic acid-inducible SEAP
expression. pPB2/pSP16-transgenic HEK-293 cells were cultivated in the presence (ON, for 6 h) or absence (OFF) of CA (100 lM). Every 24 h, the CA status of the culture was
reversed and SEAP production was profiled for up to 72 h. Data presented are mean ± SD, n P3. (This figure appears in colour on the web.)
JOURNAL OF HEPATOLOGYacid sensor was functional in different pPB2-/pSP16-co-
transfected mammalian cell lines including human ones, such
as, suspension cell lines and stem cells, suggesting that the syn-
thetic signalling cascade was broadly applicable (Fig. 1E). As
expected, possible differences in availability and compatibilityJournal of Hepatology 20of the endogenous signal transduction components with TGR5-
mediated input resulted in a wide range of induction factors
[24]. Since HEK-293 showed the best bile acid-triggered expres-
sion performance, this cell line was chosen for all further exper-
iments (Fig. 1E).16 vol. 65 j 84–94 87
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Detailed characterization of pPB2-/pSP16-co-transfected HEK-
293 cells showed that (i) the bile acid sensor neither reduced cell
viability (Supplementary Fig. 2A) nor maximum SEAP production
levels over the entire clinically relevant bile acid concentration
range (Supplementary Fig. 2B), (ii) that bile acid-triggered target
gene expression switches correlated with intracellular cAMP
levels (Supplementary Fig. 1C), (iii) that the TGR5-to-PCREm sig-
nalling could be interrupted by the PKA inhibitor H-89 confirm-
ing the exclusive rewiring (Supplementary Fig. 2C) and, most
importantly, (iv) that physiological concentrations of ligands tar-
geting HEK-293’s endogenous GPCRs sharing the cAMP pathway
did not interfere with the bile acid sensor (Supplementary
Fig. 2D), which corroborates the specificity of the biosensor and
supports previous reports that ectopic expression of GPCRs in
mammalian cells attenuates ligand-specific activation of endoge-
nous GPCRs in the same cell, likely by titrating away the endoge-
nous G-protein pool [25].
Bile acid-inducible transgene expression in mammalian cells
In order to be functional as part of a higher-order closed-loop
liver-protection device in vivo the bile acid sensor has to (i) be
sufficiently sensitive to detect the major bile-composing native
and modified bile acids within their clinically relevant concentra-
tions range, (ii) show rapid response times and induction kinetics
to manage protective and curative therapeutic responses pre-
venting liver failure, (iii) provide bile acid dose-dependent thera-
peutic transgene expression to coordinate the level of liver injury
to the level of therapeutic intervention and (iv) to deliver rever-
sible control dynamics which enable the design of a closed-loop
gene circuit that constantly adapts the therapeutic expression
dosing to the course of the liver disease and protects against liver
failure through enhanced regeneration.
Cholic acid (CA), chenodeoxycholic acid (CDCA), deoxycholic
acid (DCA), lithocholic acid (LCA) including their conjugated
(tauro- and glyco-) isoforms represent over 95% of the bile acids
found in the human serum [26]. Tauroursodeoxycholic acid
(TUDCA), a major bile acid in the serum of bears with only trace
amounts found in human and mouse sera, has been associated
with potent cytoprotective and antidiabetic activities [26–30].
Human cells containing the bile acid sensor (pPB2/pPS16) were
able to detect all (non-)conjugated human and bear bile acids
within their clinically relevant concentration range and produced
a dose-dependent reporter gene expression profile (Supplemen-
tary Fig. 3A) with rapid induction kinetics (Supplementary
Fig. 3B). As exemplified using CA as trigger bile acid, bile acid
sensor-driven expression kinetics could be precisely programmed
by the bile acid exposure time (Supplementary Fig. 3C), which
confirmed the rapid response time and induction kinetics of the
bile acid sensor. In addition, bile acid sensor-driven reporter gene
expression was reversible and showed reproducible induction
kinetics when repeatedly switched ON and OFF following addi-
tion and withdrawal of bile acids (Fig. 1F).
Bile acid-inducible protein production in serum-free suspension
cultures
Dose- and time-specific control of product gene expression in
bioreactors requires availability of gene switches that are respon-
sive to trigger cues which are generally regarded as safe (GRAS)
and licensed by food and healthcare authorities. Desoxycholic88 Journal of Hepatology 20acid is a GRAS compound that, is clinically licensed by the Food
and Drug Administration (FDA) and approved in many countries
as an emulsifier for the food industry and could therefore be
considered as a product gene expression trigger in a biopharma-
ceutical manufacturing setting. We have therefore tested desoxy-
cholic acid as trigger compound for the timely induction of the
short human glucacon-like peptide 1 (shGLP1), a long-acting
insulinogenic hormone engineered for the treatment of type 2
diabetes mellitus [31], in HEK-293-derived serum-free suspen-
sion cultures which is currently considered for the production
of viral particles for vaccines and gene therapy [32]. In standard
bioreactor operation, shGLP1-expression of HEK-293 cells trans-
genic for pPB2 and either pPB8 (PCREm-shGLP1-pA) (Fig. 2A) or
pHY67 (PCRE-shGLP1-pA) (Fig. 2B) was tightly repressed until
addition of a specific amount of desoxycholic acid which pro-
grammed the shGLP1 expression kinetics and final titer of the
production culture to specific levels (Fig. 2).
Bile acid-inducible transgene expression in mice
To validate bile acid-inducible transgene expression in vivo, we
microencapsulated pPB2/pSP16-transgenic HEK-293 cells into
clinically validated, semi-permeable and immunoprotective16 vol. 65 j 84–94
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alginate-poly-(L-lysine)-alginate beads (Fig. 3A) and implanted
them into the peritoneum of mice where they become vascular-
ized and connected to the animal’s bloodstream [33]. When mice
received increasing doses of the clinically licensed drugs CA
(Cholbam) (Fig. 3B) or tauroursodenoxycholic acid (TUDCA)
(Fig. 3C) by intraperitoneal injection, the implanted genetically
engineered cells detected circulating bile acid levels by bile acid
dose-dependent TGR5-mediated expression of SEAP (Fig. 3D),pPB2/pSP16 Mock/pSP16
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Fig. 3. Bile acid-inducible transgene expression in mice. (A) SEAP induction profiles o
co-transfected with pSP16 (PCREm-SEAP-pA) and either pPB2 (PhCMV⁄-1-TGR5-pA) or pHY7
beads. 5  103 capsules (200 cells/capsule) were cultivated in the presence or absence
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expression in mice. Wild-type mice were intraperitoneally implanted with micro
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bloodstream of treated animals were quantified 24 h and 48 h after the first bile acid adm
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Journal of Hepatology 20which reached the bloodstream and could be profiled in the
peripheral circulation of the animals (Fig. 3B, C). Likewise, the
SEAP levels in the bloodstream of treated animals could also be
modulated by intravenous injection as well as oral administra-
tion of CA (Fig. 3E) and deoxycholic acid (Fig. 3F), confirming that
the cell implant is fully integrated in the systemic circulation of
the host organism and sensitive to physiologically relevant bile
acid concentrations.0 40 80 160
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Fig. 4. The bile acid sensor detects acute liver injuries in mice. (A, B)
Chemically induced hepatotoxicity in mice. Wild-type mice were implanted with
microencapsulated TGR5/PCREm-SEAP (pPB2/pSP16, 2  106 cells, 1  104 cap-
sules, 200 cells/capsule)-transgenic HEK-293 cells and received a single oral dose
of 1 ml/kg CCl4 (carbon tetrachloride) or 75 mg/kg ANIT (alpha-naphthylisothio-
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levels or (B) alanine aminotransferase (ALT) activity was measured after 24 h and
48 h. The data are shown as the mean ± SEM, statistics by two-tailed t test, n = 8
mice. ⁄⁄⁄p <0.001 vs. control. (C) Hepatotoxicity-mediated SEAP expression in
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are shown as the mean ± SEM, statistics by two-tailed t test, n = 8 mice. n.s. (not
significant) p >0.05 vs. control.
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The bile acid sensor detects acute liver injuries in mice
The enterohepatic circulation maintains serum bile acid (SBA)
levels below 20 lM in man and mice (Fig. 4A) [4–10]. Liver inju-
ries result in imbalances of the enterohepatic circulation leading
to acute and chronically increased SBA concentrations (>20 lM in
humans), which correlate with excessive blood alanine amino-
transferase (ALT) levels (>30–40 U/L in humans and mice) that
serves as the gold standard biomarker of liver injury [34,35]. Car-
bon tetrachloride (CCl4) and alpha-naphthylisothiocyanate
(ANIT) are the reference compounds to replicate human drug-
induced hepatotoxicity in mice as they either mediate direct
destruction of hepatocytes or induce cholestasis by damaging bil-
iary epithelial cells, respectively [36,37]. When mice implanted
with pPB2/pSP16-transgenic HEK-293 cells received oral doses
of the hepatotoxicants CCl4 (1 ml/kg) or ANIT (75 mg/kg), SBA
and ALT levels immediately rose into the critical range
(Fig. 4A, B). The acute liver injury was detected and processed
by the implanted genetically engineered cell-based bile acid sen-
sor which coordinated the production, secretion and release of
the reporter protein SEAP into the bloodstream of treated animals
(Fig. 4C). The biosensor was insensitive to the minor diet-induced
SBA fluctuations (Fig. 4D) as well as oral dietary-supplement
doses of CA, deoxycholic acid and TUDCA that are expected to
be cleared by the first-pass effect of a healthy liver (Fig. 3E,
Fig. 3F, Fig. 4D). Therefore, the sensitivity of the genetically engi-
neered cell-based bile acid sensor is well suited to exclusively
detect pathologic SBA levels in the event of an acute liver injury.
Validation of a self-sufficient closed-loop liver-protection device in
mice
Advanced theranostic gene networks combine precise diagnosis
of a pathologic situation with targeted therapeutic intervention
in a closed-loop control circuit which prevents or cures a specific
disease [38]. Therefore, the design of a liver-protection device
requires functional interconnection of the bile acid sensor with
expression of a therapeutic protein that can prevent liver failure
and restore liver function. The human HGF, a secreted protein
associated with tissue protection, organ regeneration and wound
healing, has recently come into the limelight for the treatment of
various organ injuries. Unfortunately, the short half-life (<5 min,
[39–41]) of HGF in circulation would require repeated high-dose
injections which exacerbates its use as a biopharmaceutical for
the time being. However, human clinical trials have shown that
in situ production of HGF using a gene therapy approach may pro-
vide the full scope of HGF’s therapeutic potential [18–21].
We have therefore linked SBA-triggered activation of TGR5
(pPB2, PhCMV⁄-1-TGR5-pA) to PCREm-driven expression of HGF
(pPB5, PCREm-HGF-pA). In vitro validation of pPB2-/pPB5-
transgenic HEK-293 cells confirmed that the genetically
engineered cells were able to secrete clinically relevant levels
(Supplementary Fig. 4A) of bioactive HGF (Supplementary Fig. 4B)
in response to liver injury-associated bile acid concentrations.
When implanting the same cells into mice, the animals were pro-
tected from ANIT-induced liver failure and showed significantly
reduced blood values of ALT activity (Fig. 5A), SBA levels
(Fig. 5B) or bilirubin concentration (Fig. 5C), while the serum
levels of all these liver injury-specific biomarkers were dramati-
cally increased in mice treated with placebo implants. Most
importantly, the liver-protection device drove high-level HGF90 Journal of Hepatology 2016 vol. 65 j 84–94
DPlace
bo/ve
hicle
LivPr
o/veh
icle
LivPr
o/AN
IT
Place
bo/A
NIT
P hCMV
-HGF
/ANIT
0
5
10
15
20
25
H
um
an
 H
G
F 
co
nc
en
tra
tio
n 
(p
g/
m
l)
***
ND NDND
B
Place
bo LivPr
o
LivPr
o
Place
bo
0
500
1000
1500
2000
S
er
um
 to
ta
l b
ile
 a
ci
d 
(µ
M
)
***
Diluent
ANIT (75 mg/kg)
P hCMV
-HGF
0
50
100
150
200
250
300
350
A
LT
 a
ct
iv
ity
 (m
U
/m
l)
***
Diluent
ANIT (75 mg/kg)
A
Place
bo LivPr
o
LivPr
o
Place
bo
P hCMV
-HGF
C
0 2 4 6 8
Total bilirubin (mg/dl)
LivPro/vehicle
LivPro/ANIT
PhCMV -HGF/ANIT
Placebo/ANIT
Mice serum (n = 8)
Fig. 5. Self-sufficient SBA-mediated activation of HGF expression in animals treated with the liver-protection device. (A-D) Animals received either genetically
engineered cell implants (5  106 cells, 25000 capsules, 200 cells/capsule) containing the liver-protection device (pPB2/pPB5; PhCMV⁄-1-TGR5-pA/
PCREm-HGF-pA), a placebo device (pPB2/pSP16; PhCMV⁄-1-TGR5-pA/PCREm-SEAP-pA; negative control) or a constitutive HGF expression unit (pPB7; PhCMV-HGF-pA; positive
control) and were treated with a single dose of either ANIT (75 mg/kg in olive oil) or the diluent olive oil (8 ml/kg). (A) Alanine aminotransferase (ALT) activity, (B) total
serum bile acid levels and (C) bilirubin levels in sampled mouse serum were measured 48 h after oral administration of hepatotoxicants. The data are shown as the
mean ± SEM, statistics by two-tailed t test, n = 8 mice. ⁄⁄⁄p <0.001. (D) Serum HGF concentration of corresponding treatment groups shown in (A–C). The data are shown as
the mean ± SEM, statistics by two-tailed t test, n = 8 mice. ⁄⁄⁄p <0.001. n.d.: not detected (detection limit 3 pg/ml). LivPro, liver-protection device (pPB2/pPB5). (This figure
appears in colour on the web.)
JOURNAL OF HEPATOLOGYproduction exclusively following ANIT-triggered increase of SBA
levels (Fig. 5D). Histological analysis of the liver of treated ani-
mals corroborated the finding that the liver-protection device
was able to prevent drug-induced hepatotoxicity: Mice contain-
ing the liver-protecting genetically engineered cell implant
showed no signs indicative of parenchymal necrosis and inflam-
matory cell infiltrations that are typically observed following
liver injury (Fig. 6; Supplementary Fig. 5).Discussion
Synthetic biology, the engineering science of reassembling stan-
dardized biological parts in a systematic, rational and predictable
manner to program novel cellular behaviour, has enabled the
design of theranostic circuits that seamlessly couple biosensor-
based detection of disease metabolites to an automated and
self-sufficient expression of therapeutic transgenes [38,42–44].
By functionally interconnecting the bile acid sensor TGR5 via a
synthetic signalling cascade to a modified promoter and expres-
sion of the biopharmaceutical HGF, we have designed a theranos-
tic liver-protection device that enables genetically engineered
cells to interface with the host metabolism by constantly measur-
ing SBA levels. Whenever SBA levels reach a critical concentrationJournal of Hepatology 20indicative of liver damage, the liver-protection device coordi-
nated the production of HGF in a closed-loop manner by match-
ing diagnosis of liver injuries with liver-protecting therapy.
Importantly, the human TGR5 receptor used as the sensor com-
ponent for the liver-protection device is sensitive to a variety of
endogenous serum bile acids within their clinically relevant con-
centration range and drives expression of therapeutic HGF levels
exclusively at pathologic SBA levels. Since TGR5 is also responsive
to the potential antidiabetic drug TUDCA, the bile acid sensor
might also be used in future gene therapy applications that cou-
ple drug-based diabetes therapy with expression of complemen-
tary biopharmaceuticals [45].
Drug-induced hepatotoxicity remains a major challenge in the
treatment of various diseases such as multidrug-resistant tuber-
culosis [46] and colorectal cancer [47]. 20% of the patients diag-
nosed with colorectal cancer have distant metastases, primarily
in the liver. Surgical resection of isolated liver metastases is the
treatment of choice [48]. When the metastases are too big for
primary surgical resection patients are first treated with
chemotherapeutic drugs aiming for size reduction that could
render them resectable [49]. However, this approach is limited
by the hepatotoxicity of the chemotherapeutic agents such as
Irinotecan or Oxaliplatin, which may trigger chemotherapy-
associated steatohepatitis, vascular injury and non-cirrhotic
portal hypertension [50]. The liver-protection device may protect16 vol. 65 j 84–94 91
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Fig. 6. Toluidine blue-based histological analysis of liver damage in animals
treated with the liver-protection device. (A–F) Animals received either no
implant or genetically engineered cell implants (5  106 cells, 25000 capsules,
200 cells/capsule) containing the liver-protection device (pPB2/pPB5;
PhCMV⁄-1-TGR5-pA/PCREm-HGF-pA), the placebo device (pPB2/pSP16;
PhCMV⁄-1-TGR5-pA/PCREm-SEAP-pA; negative control) or a constitutive HGF
expression unit (pPB7; PhCMV-HGF-pA; positive control) and were treated with
a single dose of either ANIT (75 mg/kg in olive oil) or the diluent olive oil
(8 ml/kg). (A, B) ANIT-treated animals exhibiting gradually-cumulative lesions
characterized by necrotic and hemorrhagic lesions (asterisk) located close to the
central veins (cv). The pathohistological changes revealed as the entire sequence
from normal appearance (cv1) to dilated sinusoids (cv2) and necrotic lesions
(cv3) containing infiltrations of macrophages and granulocytes (arrowhead).
(B, larger magnification of A; Scale bar A = 100 lm, B = 20 lm). (C, D)
ANIT-treated mice containing the liver-protection device show slightly dilated
sinusoidal vessels without pathological changes (D, larger magnification of C;
scale bars 100 lm (C), 20 lm (D)). (E) Control animals treated with placebo
implants and olive oil exhibit normal liver structures (scale bar 100 lm).
(F) Control animals treated with ANIT and constitutive HGF production
implants show normal liver structures (scale bar 100 lm). (This figure appears
in colour on the web.)
Research Articlethe liver during the treatment of patients with higher doses of
chemotherapeutics.
Drug-induced hepatotoxicity is an important concern in the
treatment of tuberculosis, in particular multidrug-resistant
tuberculosis, whose prevalence has reached 20% of treated cases
[46]. The first-line treatment of this infectious disease includes
Isoniazid and Rifampicin, which are hepatotoxic especially when
administered at higher doses [51,52]. Indeed, liver failure associ-
ated with anti-tuberculosis treatment is the most common acute
drug-associated liver failure in South Asia [53]. HGF has been
shown to exert liver-protective effects against Isoniazid- and
Rifampicin-induced liver damage [54]. The use of a liver-
protection device that reversibly triggers the production and
secretion of HGF in response to developing liver damage by sens-
ing bile acids may enable the use of anti-tuberculosis drugs at
higher doses while limiting the damage to the liver.92 Journal of Hepatology 20The poor pharmacokinetics of HGF so far precludes the use of
this potent biopharmaceutical. In situ production of HGF using a
gene therapy-based approach has in principle confirmed HGF’s
potential for the treatment of liver injuries and other organ insuf-
ficiencies such as diabetic neuropathy, critical limb ischemia and
ischemic cardiac disease [18–21,55]. However, the classic gene-
based treatment strategy lacks the expression dynamics and
interface with the host metabolism that is required to adapt
HGF production to the disease course in real time. Additionally,
chronic activation of the HGF receptor is associated with a variety
of cancer types [56,57], which highlights the importance of a self-
sufficient HGF production provided by the closed-loop liver-
protection device when targeting potentially fatal hepatotoxic
drug effects.
Although the liver-protection device exclusively contains
human genetic components, is engineered into human cells, and
responds to clinically relevant SBA levels, there are still several
translational challenges before genetically engineered theranostic
cells will be routinely used for human therapy. To adapt geneti-
cally engineered theranostic cells to the clinic, critical design
parameters will have to be addressed, including the use of autol-
ogous cells, scaling of the system to provide therapeutic levels of
HGF, and development of an implant that stores the genetically
engineered cells in a single device. The final therapymay be based
on patient-derived autologous cell batches that are produced,
engineered with the liver-protection device, validated for optimal
patient-specific response and dosing performance and frozen for
storage. The genetically engineered cells will be filled into appro-
priate containers and implanted into the body where they auto-
matically connect to the bloodstream [33], monitor SBA levels
and corresponding liver damage and coordinate the therapeutic
response. The genetically engineered cell implants will be prefer-
ably placed subcutaneously, since they can be removed by a min-
imal ambulant intervention in case of complications or replaced at
regular intervals (e.g., every 3–4 months) due to fibrosis.
In summary, protection of the liver from drug-induced toxic-
ities by an engineered theranostic liver-protection device may
enable novel and/or more aggressive treatments of diseases
where the use of current armamentarium is limited by severe
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